Outlook for 2025: how Trump and the USPTO will affect life sciences IP

Key developments for the industry this year include a more pro-patent administration and USPTO changes, say Carla Ji-Eun Kim and Deborah Sterling of Sterne Kessler.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Oracle retaliates with lawsuit to laid-off staff member’s ‘demands’

13 April 2026 The US tech company targets a disgruntled ex-employee for threatening to sell its trade secrets if he does not receive an “unreasonable fee”.

Americas

LSPN Awards USA: Meet the judges

10 April 2026 The 2026 panel has been chosen. With judges from Amgen, Pfizer, Eli Lilly, Takeda, Regeneron and law firms such as White & Case and Arnold & Porter, here’s who will be deciding this year’s winners.

Americas

Bausch reaches deal with competitor over IBS drug generic

7 April 2026 According to the settlement, MSN can maintain its challenge to several Bausch patents, while the details around potential product launch timings are unknown.

More features

Oracle retaliates with lawsuit to laid-off staff member’s ‘demands’

LSPN Awards USA: Meet the judges

UK patent office adopts EPO standards for AI inventions

Gilead to pay up to $5bn for antibody-drug conjugates push

Closing the women's health gap offers ‘benefits for all’

Bausch reaches deal with competitor over IBS drug generic

UPC refuses early knockout in Illumina–Element dispute

Argentina’s patent reset: Why pharma can no longer ignore Latin America's second-largest market

Outlook for 2025: how Trump and the USPTO will affect life sciences IP

More on this story

Editor's picks

Editor's picks

More features